Company RenovoRx, developing a medical device for the treatment of solid tumors, attracted 17 million dollars, releasing 1,85 million packages of 9 Dollars, minimum price of the revised range from 9 to 11 Dollars. Each package consists of one ordinary share and one order, due on 10,80 Dollars.
Initially, the company applied for the issue of shares at a price of 12 to 14 Dollars, however, after twice reducing the declared range. Taking into account the actual IPO price, the total diluted market value of RenovoRx will be about 115 million dollars.
RenovoRx Plans to List Common Shares on the Exchange Nasdaq under the ticker RNXT. Roth Capital became the sole organizer of the share issue.
